Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Evofem Biosciences's operating margin for the twelve months ending Jun 30, 2026 was -15.3%. For fiscal 2025 it was 16.7%, against -39.6% the year before. The highest annual figure on record is 16.7% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.7% | +56.3 |
| FY2024 | Dec 31, 2024 | -39.6% | +58.3 |
| FY2023 | Dec 31, 2023 | -98.0% | +401.7 |
| FY2022 | Dec 31, 2022 | -499.6% | +1523.7 |
| FY2021 | Dec 31, 2021 | -2023.3% | +21210.8 |
| FY2020 | Dec 31, 2020 | -23234.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -94.5% | −68.6 |
| Q1 FY2026 | Mar 31, 2026 | -508.2% | −546.9 |
| Q4 FY2025 | Dec 31, 2025 | 35.0% | +49.1 |
| Q3 FY2025 | Sep 30, 2025 | 19.2% | +73.5 |
| Q2 FY2025 | Jun 30, 2025 | -25.9% | +7.5 |
| Q1 FY2025 | Mar 31, 2025 | 38.7% | +117.6 |
| Q4 FY2024 | Dec 31, 2024 | -14.1% | +284.3 |
| Q3 FY2024 | Sep 30, 2024 | -54.3% | +7.3 |
| Q2 FY2024 | Jun 30, 2024 | -33.4% | +6625.2 |
| Q1 FY2024 | Mar 31, 2024 | -78.9% | +215.0 |
| Q2 FY2023 | Jun 30, 2023 | -298.5% | +106.2 |
| Q1 FY2023 | Mar 31, 2023 | -61.6% | +618.9 |
| Q4 FY2022 | Dec 31, 2022 | -6658.6% | −5610.4 |
| Q3 FY2022 | Sep 30, 2022 | -293.9% | +2239.3 |
| Q2 FY2022 | Jun 30, 2022 | -404.7% | +1810.8 |
| Q1 FY2022 | Mar 31, 2022 | -680.5% | +3380.3 |
| Q4 FY2021 | Dec 31, 2021 | -1048.1% | +20291.8 |
| Q3 FY2021 | Sep 30, 2021 | -2533.2% | +6875.4 |
| Q2 FY2021 | Jun 30, 2021 | -2215.5% | – |
| Q1 FY2021 | Mar 31, 2021 | -4060.8% | – |
| Q4 FY2020 | Dec 31, 2020 | -21339.9% | – |
| Q3 FY2020 | Sep 30, 2020 | -9408.6% | – |
See a number that looks wrong?